Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Essential Thrombocythemia Myelofibrosis (Post-ET...
Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF)....
Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval
Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Ankylosing Spondylitis (Bekhterev's Disease)....
ZG-005 by Suzhou Zelgen Biopharmaceutical for Neuroendocrine Carcinoma: Likelihood of Approval
ZG-005 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData,...
ZG-005 by Suzhou Zelgen Biopharmaceutical for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
ZG-005 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...
ZG-005 by Suzhou Zelgen Biopharmaceutical for Hepatocellular Carcinoma: Likelihood of Approval
ZG-005 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...
Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Alopecia Areata: Likelihood of Approval
Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Alopecia Areata. According to...
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Solid Tumor: Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Solid Tumor. According to...
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Head And Neck Squamous...
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Hepatocellular Carcinoma: Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Hepatocellular Carcinoma. According to...
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma)....
Donafenib tosylate by Suzhou Zelgen Biopharmaceutical for Endometrial Cancer: Likelihood of Approval
Donafenib tosylate is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase I for Endometrial Cancer. According to...
Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval
Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary...
Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval
Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Ankylosing Spondylitis (Bekhterev's Disease)....
Jaktinib hydrochloride by Suzhou Zelgen Biopharmaceutical for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF)....